Integra Therapeutics, a global leader in cutting-edge gene writing tools designed to improve the efficacy, precision, and safety of advanced therapies, has closed a €10.7 million pre-Series A investment round. New investors include the EIC Fund — the venture capital arm of the European Innovation Council (EIC), with the European Investment Bank (EIB) as the investor of record — contributing €4 million, and CDTI Innvierte of the Spanish Ministry of Science, Innovation, and University, contributing €2.7 million. Existing investors AdBio Partners, Columbus Venture Partners, Invivo Partners, and Takeda Ventures also participated, continuing to support the company’s vision.
The funding will enable the incorporation of new advances into the FiCAT gene writing platform, validation of next-generation CAR-T therapies in the preclinical phase, and expansion of FiCAT cell engineering capabilities to facilitate technology transfer to the pharmaceutical industry. In May, new, highly promising preclinical data for the FiCAT platform was presented at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT).
Additionally, Integra Therapeutics is advancing its first gene therapy for a rare pediatric liver disease, supported by an EIC Accelerator grant.
“Thanks to the support of our investors, we will continue leading innovation in cell and gene therapies and are getting closer to transforming the treatment of complex diseases like cancer, autoimmune diseases and rare diseases,” explains Avencia Sánchez-Mejías, PhD, CEO and Co-Founder of Integra Therapeutics.
“We are happy to announce EIC Fund’s investment in Integra Therapeutics. We empower them to accelerate the development of groundbreaking therapies that have the potential to transform lives and advance the field of gene therapy on a global scale,” says Svetoslava Georgieva, Chair of the EIC Fund Board.